CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- FinancialsAltman Z-Score -3.35: distress zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.16BUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
0.9420xvs all stocks
52-Week Change
184.79%vs all stocks
Market Capitalization
1.16BUSDvs all stocks (USD)
Enterprise Value
1.08BUSDvs all stocks (USD)
Forward P/E
-6.06xvs Biotechnology peers
Price to Book (MRQ)
9.83xvs Biotechnology peers
Enterprise to EBITDA
-3.72xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-51.30%vs Biotechnology peers
Return on Equity (TTM)
-134.29%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Sep 28, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
-290.44MUSDvs all stocks (USD)
Net Income (TTM)
-297.01MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-279.06MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-171.67MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2026 · Mar 31, 2026Operating Income
-318.31MUSDvs all stocks (USD)
Pre-tax Income
-314.49MUSDFY2026 · Mar 31, 2026Income Tax Expense
-551.00KUSDFY2026 · Mar 31, 2026Net Income
-313.94MUSDFY2026 · Mar 31, 2026EBIT
-305.63MUSDFY2026 · Mar 31, 2026EBITDA (Income Statement)
-315.93MUSDFY2026 · Mar 31, 2026Research & Development
221.18MUSDFY2026 · Mar 31, 2026Selling, General & Administrative
98.73MUSDFY2026 · Mar 31, 2026Other Operating Expenses
-1.60MUSDFY2026 · Mar 31, 2026Non-operating Interest Expense
8.86MUSDFY2026 · Mar 31, 2026EPS (Basic)
-3.38USDFY2026 · Mar 31, 2026EPS (Diluted)
-3.38USDFY2026 · Mar 31, 2026Basic Shares Outstanding
92.80MSharesFY2026 · Mar 31, 2026Diluted Shares Outstanding
92.80MSharesFY2026 · Mar 31, 2026Net Income from Continuing Operations
-313.94MUSDFY2026 · Mar 31, 2026Operating Cash Flow
-279.00MUSDFY2026 · Mar 31, 2026Free Cash Flow
-283.22MUSDFY2026 · Mar 31, 2026Cash & Cash Equivalents (End of Period)
210.73MUSDFY2026 · Mar 31, 2026Income Tax Paid
5.00KUSDFY2026 · Mar 31, 2026Interest Paid
4.69MUSDFY2026 · Mar 31, 2026Starting Profit (CF Statement)
-313.94MUSDFY2026 · Mar 31, 2026Depreciation & Amortization
3.33MUSDFY2026 · Mar 31, 2026Stock-based Compensation
32.27MUSDFY2026 · Mar 31, 2026Other Non-cash Items
5.13MUSDFY2026 · Mar 31, 2026Change in Accounts Receivable (CF)
451.00KUSDFY2026 · Mar 31, 2026Change in Accounts Payable (CF)
-4.94MUSDFY2026 · Mar 31, 2026Change in Other Assets/Liabilities
-1.30MUSDFY2026 · Mar 31, 2026Capital Expenditures
-4.22MUSDFY2026 · Mar 31, 2026Purchase of Investments
-77.89MUSDFY2026 · Mar 31, 2026Sale of Investments
392.96MUSDFY2026 · Mar 31, 2026Net Investing Cash Flow
310.84MUSDFY2026 · Mar 31, 2026Long-term Debt Issuance
35.00MUSDFY2026 · Mar 31, 2026Long-term Debt Payments
-736.00KUSDFY2026 · Mar 31, 2026Net Financing Cash Flow
65.41MUSDFY2026 · Mar 31, 2026Shares Outstanding
83.98MSharesUpdated Sep 28, 2026Float Shares
67.65MSharesUpdated Sep 28, 2026Shares Short
22.75MSharesUpdated Sep 28, 2026Short Ratio
9.39daysvs all stocks
Short % of Shares Outstanding
33.69%vs all stocks
% Held by Insiders
1.65%vs all stocks
% Held by Institutions
104.25%vs all stocks
Total Cash (MRQ)
195.33MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
2.07USDUpdated Sep 28, 2026Total Debt (MRQ)
111.97MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
1.06xvs Biotechnology peers
Current Ratio (MRQ)
5.23xvs Biotechnology peers
Book Value per Share (MRQ)
1.26USDUpdated Sep 28, 2026Total Assets
332.39MUSDvs all stocks (USD)
Total Current Assets
279.12MUSDFY2026 · Mar 31, 2026Total Liabilities
166.23MUSDFY2026 · Mar 31, 2026Total Non-current Assets
53.27MUSDFY2026 · Mar 31, 2026Total Non-current Liabilities
108.00MUSDFY2026 · Mar 31, 2026Total Current Liabilities
58.23MUSDFY2026 · Mar 31, 2026Cash
88.72MUSDFY2026 · Mar 31, 2026Cash Equivalents
120.30MUSDFY2026 · Mar 31, 2026Cash & Cash Equivalents
209.02MUSDFY2026 · Mar 31, 2026Other Short-term Investments
59.87MUSDFY2026 · Mar 31, 2026Accounts Payable
6.67MUSDFY2026 · Mar 31, 2026Short-term Debt
4.04MUSDFY2026 · Mar 31, 2026Other Current Liabilities
2.76MUSDFY2026 · Mar 31, 2026Long-term Debt
107.55MUSDFY2026 · Mar 31, 2026Other Non-current Liabilities
455.00KUSDFY2026 · Mar 31, 2026Common Stock (Book)
82.00KUSDFY2026 · Mar 31, 2026Retained Earnings
-1.26BUSDFY2026 · Mar 31, 2026Total Shareholders' Equity
166.16MUSDvs all stocks (USD)
52-Week Low
1.50USDUpdated Sep 28, 202652-Week High
16.33USDUpdated Sep 28, 202652-Week Change
184.79%vs all stocks
Beta
0.9420xvs all stocks
50-Day MA
12.90USDUpdated Sep 28, 2026200-Day MA
8.83USDUpdated Sep 28, 2026Avg 10-Day Volume
1.89MSharesUpdated Sep 28, 2026Avg 30-Day Volume
2.25MSharesUpdated Sep 28, 2026Diluted EPS (TTM)
-3.15USDUpdated Sep 28, 2026Other Income / Expense
12.68MUSDFY2026 · Mar 31, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 5.23Altman Z-Score: -3.35
Financial Health
Altman Z-Score -3.35: distress zoneCritical
Altman Z-Score: -3.35
Low earnings qualitySignificant
Earnings Quality Score: -0.68
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 33,357,653.812
Companies that share the same coordination system — how they create, deliver, or capture value.
Sanofi Consumer Healthcare Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Tianjin Ringpu Bio-Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Glass House Brands Inc.
Tier 1ProductionApproval-Gated PipelineFlowRule
Beta Bionics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Avanos Medical Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Beijing Winsunny Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hunan Warrants Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Harbin Gloria Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Chongqing Taiji Industry Group Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Innovita Biological Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule